OR WAIT null SECS
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
August 17, 2023
Experts discuss the promise of personalized cancer vaccines through the inherent nimbleness of mRNA platform.
August 03, 2023
A comprehensive understanding of what makes mRNA vaccines tick is crucial in charting the future of the market.
August 02, 2023
Current good manufacturing practices for oral solid dosage forms protect the product from contamination and potential errors.
July 27, 2023
Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.
July 18, 2023
Jeff Fischer, co-founder and president of Longhorn Vaccines and Diagnostics, discusses the history and ongoing development of both protein- and mRNA-based vaccines.
July 11, 2023
In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.
July 05, 2023
When evaluating a drug’s risk assessment for elemental impurities, one must consider all aspects of its lifecycle.
July 03, 2023
FDA’s new guidance on in-vitro permeation test studies published in October 2022 gives technical and statistical requirements for conducting these tests to compare topical generic drugs with their reference products.
June 13, 2023
Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on percent transduction for AAV measured.
June 06, 2023
invoX Pharma has made a second tranche of investment in pHion Therapeutics to support further development of next-generation mRNA vaccines.